The unexpected success of NRTIs in second-line treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe.PloS one · 2021
   Trial
2. The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study.The lancet. HIV · 2025
   Article
3. Roadmap for Achieving Universal Antiretroviral Treatment.Annual review of pharmacology and toxicology · 2023
   Review
4. Outcomes and characteristics of patients on protease inhibitors at a tertiary level antiretroviral clinic.Southern African journal of HIV medicine · 2023
   Article
5. Salvage Antiretroviral Therapy: Time for "DeNUKElearization"?The Journal of infectious diseases · 2020
   Article
6. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
   Article
7. Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models.Journal of medical economics · 2020
   Article
8. Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update.Southern African journal of HIV medicine · 2020
   Article
9. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.The lancet. HIV · 2018
   Article

Corrections and comments

• Comment on
  Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as